Coding polymorphisms in the genes of the alternative complement pathway and abdominal aortic aneurysm.
D T Bradley1, S A Badger, M J Bown
1Centre for Public Health, Institute of Clinical Sciences, Queen's University Belfast, Royal Victoria Hospital, Grosvenor Road, Belfast, UK. dbradley09@qub.ac.uk
International Journal of Immunogenetics
|March 1, 2011
Summary
Genetic variations in the alternative complement pathway are not strongly linked to abdominal aortic aneurysm development. This study found no significant association between these gene variants and the presence or size of aortic aneurysms.
Area of Science:
- Genetics
- Immunology
- Cardiovascular Disease
Background:
- Abdominal aortic aneurysm (AAA) is a significant cause of mortality, particularly in European populations.
- Inflammation plays a key role in the pathogenesis of AAA.
- The alternative complement pathway is implicated in various inflammatory conditions.
Purpose of the Study:
- To investigate the association between genetic variants in the alternative complement pathway and the risk of developing abdominal aortic aneurysm.
- To determine if specific single nucleotide polymorphisms (SNPs) in complement genes are linked to AAA presence or size.
Main Methods:
- Genotyping of 49 single nucleotide polymorphisms (SNPs) in 18 genes of the alternative complement cascade.
- Case-control study design involving 434 patients with AAA and 378 healthy controls of European ancestry from UK centers.
- Statistical analysis to assess the association between SNPs and AAA, with correction for multiple testing.
Main Results:
- No statistically significant association was found between the tested variants in the alternative complement pathway genes and the presence or size of abdominal aortic aneurysms after correcting for multiple testing.
- This suggests that common variations within these specific complement genes do not significantly contribute to AAA development in the studied population.
Conclusions:
- Variation in the genes of the alternative complement pathway does not appear to be a major etiological factor in the development of abdominal aortic aneurysm.
- Further research may be needed to explore other genetic or environmental factors contributing to AAA pathogenesis.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
02:18Alternative RNA Splicing
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Complement System
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
01:32RNA Splicing
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...